Properties
What is it?
Trade name of the preparation: PANANGIN® (PANANGIN®) International Nonproprietary Name (INN): Not applicable Dosage form: Concentrate for solution for infusion Composition Active substances: Potassium aspartate 452 mg (in the form of potassium aspartate hemihydrate 475.73 mg) and magnesium aspartate 400 mg (in the form of magnesium aspartate tetrahydrate 499.80 mg) in each 10 ml ampoule. Excipients: Water for injections. Description Colorless or slightly greenish, transparent solution. Pharmacotherapeutic group: Intravenous infusion solutions. Solutions affecting electrolyte balance. Pharmacological properties Pharmacodynamics Potassium and magnesium ions are important intracellular cations necessary for the functioning of a number of enzymes, for the binding of macromolecules to subcellular structures, as well as for the molecular mechanism of muscle contraction. The ratio of extracellular and intracellular concentrations of potassium, calcium, sodium, and magnesium ions affects the contractility of the myocardium. Aspartate is an endogenous substance - a carrier of potassium and magnesium ions; it has a pronounced affinity for cells, but its salts dissociate weakly. As a result, ions enter the intracellular space in the form of complex compounds. Magnesium and potassium aspartates improve myocardial metabolism. Insufficient content of magnesium and potassium in the body increases the risk of developing arterial hypertension, atherosclerotic lesions of the coronary arteries, cardiac rhythm disturbances, and myocardial pathology. Pharmacokinetics Data are not available. Indications for use The preparation is indicated for additional therapy in chronic heart diseases (in heart failure, in the post-infarction period), cardiac rhythm disturbances, primarily ventricular arrhythmias. As additional therapy in combination with cardiac glycoside preparations. Contraindications Acute and chronic renal failure, Addison's disease, atrioventricular block grade III, cardiogenic shock (BP < 90 mmHg). Hypersensitivity to the active substances of the preparation or to any of the substances listed in the "Composition" section. Use during pregnancy and lactation No harmful effects of the preparation have been recorded in patients of these categories to date. Method of administration and dosage The preparation is intended for intravenous administration only. For this purpose, the contents of 1-2 ampoules are diluted in 5% glucose solution and administered intravenously by slow drip infusion. If necessary, this dose can be repeated after 4-6 hours. The preparation can be used in combination therapy. Side effects Disorders of metabolism and nutrition Too rapid administration can cause symptoms of hyperkalemia/hypermagnesemia. Reporting of suspected adverse reactions Reporting of suspected adverse reactions is important after the medicinal product is registered and allows for continuous monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are recommended to report any suspected adverse reactions to the medicinal product through the national reporting system. If any of the listed side effects are exacerbated, or if you notice any other side effects not described in the instructions, please inform your doctor. Overdose No cases of overdose have been reported to date. The risk of hyperkalemia and hypermagnesemia increases in case of overdose. Symptoms of hyperkalemia: fatigue, muscle weakness, paresthesia, confusion, impaired cardiac function (bradycardia, atrioventricular block, arrhythmias, cardiac arrest). Symptoms of hypermagnesemia: decreased neuromuscular excitability, vomiting, nausea, drowsiness, decreased blood pressure. With very high concentrations of magnesium ions in the blood: suppression of deep tendon reflexes, respiratory paralysis, coma. In case of overdose, treatment with PANANGIN® should be discontinued and symptomatic treatment should be carried out (intravenous administration of calcium chloride at a dose of 100 mg/min, hemodialysis if necessary). Interaction with other medicinal products Combination of the preparation with potassium-sparing diuretics and/or ACE inhibitors may cause hyperkalemia. Precautions Rapid administration may cause facial hyperemia. Special caution is required when prescribing the preparation to patients with diseases accompanied by hyperkalemia. Regular monitoring of electrolyte concentrations in blood serum is recommended in this category of patients. Effect on ability to drive and operate machinery The preparation does not affect the ability to drive vehicles and operate other machinery. Packaging 10 ml of the preparation in a colorless glass ampoule (1 hydrolytic class) with a breaking point and a marking ring, 5 ampoules in a plastic tray with or without a polymer film. 1 plastic tray in a cardboard box together with instructions for medical use. Storage conditions The medicinal product does not require special storage conditions. Keep out of reach of children. Shelf life 3 years. Do not use after the expiry date indicated on the packaging. Dispensing regime: Pharmaceutical product group - II, dispensed with prescription form No. 3